AU2003249604B2 - A2B adenosine receptor antagonists - Google Patents

A2B adenosine receptor antagonists Download PDF

Info

Publication number
AU2003249604B2
AU2003249604B2 AU2003249604A AU2003249604A AU2003249604B2 AU 2003249604 B2 AU2003249604 B2 AU 2003249604B2 AU 2003249604 A AU2003249604 A AU 2003249604A AU 2003249604 A AU2003249604 A AU 2003249604A AU 2003249604 B2 AU2003249604 B2 AU 2003249604B2
Authority
AU
Australia
Prior art keywords
dione
trihydropurine
formula
compound
dipropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003249604A
Other languages
English (en)
Other versions
AU2003249604A1 (en
Inventor
Elfatih Elzein
Prabha Ibrahim
Rao Kalla
Xiaofen Li
Venkata Palle
Thao Perry
Vaibhav Varkhedkar
Dengming Xiao
Jeff Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2003249604A1 publication Critical patent/AU2003249604A1/en
Assigned to GILEAD PALO ALTO, INC. reassignment GILEAD PALO ALTO, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CV THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2003249604B2 publication Critical patent/AU2003249604B2/en
Priority to AU2011224104A priority Critical patent/AU2011224104B2/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. Request for Assignment Assignors: GILEAD PALO ALTO, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2003249604A 2003-05-06 2003-05-06 A2B adenosine receptor antagonists Ceased AU2003249604B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011224104A AU2011224104B2 (en) 2003-05-06 2011-09-16 A2B adenosine receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/014085 WO2004106337A1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011224104A Division AU2011224104B2 (en) 2003-05-06 2011-09-16 A2B adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
AU2003249604A1 AU2003249604A1 (en) 2005-01-21
AU2003249604B2 true AU2003249604B2 (en) 2011-06-30

Family

ID=33488737

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003249604A Ceased AU2003249604B2 (en) 2003-05-06 2003-05-06 A2B adenosine receptor antagonists

Country Status (15)

Country Link
EP (1) EP1622908B1 (enExample)
JP (1) JP2006515316A (enExample)
CN (1) CN100590125C (enExample)
AT (1) ATE403656T1 (enExample)
AU (1) AU2003249604B2 (enExample)
CA (1) CA2524778C (enExample)
CY (1) CY1108457T1 (enExample)
DE (1) DE60322748D1 (enExample)
DK (1) DK1622908T3 (enExample)
ES (1) ES2311759T3 (enExample)
MX (1) MXPA05011860A (enExample)
NZ (1) NZ543416A (enExample)
PT (1) PT1622908E (enExample)
SI (1) SI1622908T1 (enExample)
WO (1) WO2004106337A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
EP2970303B3 (en) * 2013-03-15 2018-08-01 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
US11045472B2 (en) * 2017-05-05 2021-06-29 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
US20210040097A1 (en) * 2018-03-05 2021-02-11 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
CN118459463B (zh) * 2024-07-10 2024-09-06 山东中医药大学附属医院 一种化合物及其制备方法和治疗2型糖尿病的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879296A (en) * 1985-04-27 1989-11-07 Burroughs Wellcome Co. Xanthine derivatives
WO2000073307A2 (en) * 1999-06-01 2000-12-07 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4878296A (en) * 1988-04-22 1989-11-07 The United States Of America As Represented By The Secretary Of The Navy Apparatus and method for locating the axis of symmetry (center of circular cross section) of three dimensional objects
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
ES2189079T3 (es) * 1998-04-24 2003-07-01 Leuven K U Res & Dev Efectos inmunosupresores de derivados de xantina 8-sustituidos.
KR100883292B1 (ko) * 2001-06-29 2009-02-11 씨브이 쎄러퓨틱스, 인코포레이티드 A2b 아데노신 수용체 길항제로서의 퓨린 유도체
PT1444233E (pt) * 2001-11-09 2011-09-29 Gilead Palo Alto Inc Antagonistas de receptor de adenosina a2b
WO2003063800A2 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879296A (en) * 1985-04-27 1989-11-07 Burroughs Wellcome Co. Xanthine derivatives
WO2000073307A2 (en) * 1999-06-01 2000-12-07 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors

Also Published As

Publication number Publication date
NZ543416A (en) 2009-01-31
EP1622908A1 (en) 2006-02-08
HK1092137A1 (en) 2007-02-02
DE60322748D1 (de) 2008-09-18
MXPA05011860A (es) 2006-02-17
JP2006515316A (ja) 2006-05-25
CN100590125C (zh) 2010-02-17
PT1622908E (pt) 2008-11-14
EP1622908B1 (en) 2008-08-06
ATE403656T1 (de) 2008-08-15
AU2003249604A1 (en) 2005-01-21
SI1622908T1 (sl) 2008-12-31
CN1771250A (zh) 2006-05-10
DK1622908T3 (da) 2008-11-17
ES2311759T3 (es) 2009-02-16
CA2524778A1 (en) 2004-12-09
WO2004106337A1 (en) 2004-12-09
CA2524778C (en) 2013-01-29
CY1108457T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
US6977300B2 (en) A2B adenosine receptor antagonists
US8324224B2 (en) A2B adenosine receptor antagonists
EP1444233B1 (en) A2b adenosine receptor antagonists
AU2002359365A1 (en) A2B adenosine receptor antagonists
AU2003249604B2 (en) A2B adenosine receptor antagonists
US7304070B2 (en) A2B adenosine receptor antagonists
AU2011224104B2 (en) A2B adenosine receptor antagonists
RU2318825C2 (ru) Производные ксантина в качестве антагонистов a2b аденозинового рецептора
HK1092137B (en) Xanthine derivatives as a2b adenosine receptor antagonists
ES2368998T3 (es) Antagonistas del receptor de adenosina a2b.
HK1071127B (en) A2b adenosine receptor antagonists
NZ573577A (en) Xanthine derivatives as A2B adenosine receptor antagonists suitable for treating conditions such as asthma and diarrhoea
KR20060055453A (ko) A2b 아데노신 수용체 길항제로서의 크산틴 유도체
ZA200508262B (en) Xanthine derivatives as A2B adenosine receptor antagonists

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ A2B ADENOSINE RECEPTOR ANTAGONISTS

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER WAS: GILEAD PALO ALTO, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired